Trial reportJournal of the International Neuropsychological Society : JINS2018
Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults.
Trial report in Journal of the International Neuropsychological Society : JINS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Amphetamine improves mouse and human attention in the 5-choice continuous performance test.Neuropharmacology · 2018Trial
- Amphetamine increases timing variability by degrading prefrontal temporal encoding.Neuropharmacology · 2025Article
- Maximising translational value of the Iowa gambling task in preclinical studies through the use of the rodent touchscreen.Frontiers in psychiatry · 2025Review
- Attenuating midline thalamus bursting to mitigate absence epilepsy.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Relationship between two forms of impulsivity in mice at baseline and under acute and sub-chronic atomoxetine treatment.Progress in neuro-psychopharmacology & biological psychiatry · 2023Article
- Poor inhibitory control predicts sex-specific vulnerability to nicotine rewarding properties in mice.Psychopharmacology · 2023Article
- The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.Current topics in behavioral neurosciences · 2022Article
- Preclinical Evaluation of Attention and Impulsivity Relevant to Determining ADHD Mechanisms and Treatments.Current topics in behavioral neurosciences · 2022Article
- Which came first: Cannabis use or deficits in impulse control?Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence.Drug and alcohol dependence · 2020Article
- Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment.Psychopharmacology · 2020Article
- Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research.Frontiers in pharmacology · 2020Article
- Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.Psychopharmacology · 2019Article
- Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesAmphetamine improves vigilance as assessed by continuous performance tests (CPT) in children and adults with attention deficit hyperactivity disorder (ADHD). Less is known, however, regarding amphetamine effects on vigilance in healthy adults. Thus, it remains unclear whether amphetamine produces general enhancement of vigilance or if these effects are constrained to the remediation of deficits in patients with ADHD.
methodsWe tested 69 healthy adults (35 female) on a standardized CPT (Conner's CPT-2) after receiving 10- or 20-mg d-amphetamine or placebo. To evaluate potential effects on learning, impulsivity, and perseveration, participants were additionally tested on the Iowa Gambling Task (IGT) and Wisconsin Card Sorting Task (WCST).
resultsParticipants receiving placebo exhibited the classic vigilance decrement, demonstrated by a significant reduction in attention (D') across the task. This vigilance decrement was not observed, however, after either dose of amphetamine. Consistent with enhanced vigilance, the 20-mg dose also reduced reaction time variability across the task and the ADHD confidence index. The effects of amphetamine appeared to be selective to vigilance since no effects were observed on the IGT, WCST, or response inhibition/perseveration measures from the CPT.
conclusionsThe present data support the premise that amphetamine improves vigilance irrespective of disease state. Given that amphetamine is a norepinephrine/dopamine transporter inhibitor and releaser, these effects are informative regarding the neurobiological substrates of attentional control. (JINS, 2018, 24, 283-293).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.